Cellectar Biosciences Inc... (CLRB)
NASDAQ: CLRB
· Real-Time Price · USD
0.36
-0.05 (-11.79%)
At close: Jun 06, 2025, 3:13 PM
-11.79% (1D)
Bid | 0.28 |
Market Cap | 16.59M |
Revenue (ttm) | n/a |
Net Income (ttm) | -24.54M |
EPS (ttm) | -0.63 |
PE Ratio (ttm) | -0.57 |
Forward PE | -0.74 |
Analyst | Buy |
Ask | 0.36 |
Volume | 8,108,167 |
Avg. Volume (20D) | 11,529,825 |
Open | 0.39 |
Previous Close | 0.41 |
Day's Range | 0.34 - 0.40 |
52-Week Range | 0.22 - 3.42 |
Beta | 0.52 |
About CLRB
undefined
Industry n/a
Sector n/a
IPO Date n/a
Employees NaN
Stock Exchange n/a
Ticker Symbol CLRB
Website n/a
Analyst Forecast
According to 0 analyst ratings, the average rating for CLRB stock is "n/a." The 12-month stock price forecast is $n/a, which is a decrease of 0% from the latest price.
Stock Forecasts1 day ago
-11.61%
Cellectar Biosciences shares are trading lower. Th...
Unlock content with
Pro Subscription
2 days ago
+66.32%
Cellectar Biosciences shares are trading higher after the company announced it was granted FDA Breakthrough Therapy Designation status for Iopofosine I-131.

3 weeks ago · seekingalpha.com
Cellectar Biosciences Inc. (CLRB) Q1 2025 Earnings Call TranscriptCellectar Biosciences Inc. (NASDAQ:CLRB ) Q1 2025 Earnings Conference Call May 13, 2025 8:30 AM ET Company Participants Jim Caruso - President and CEO Chad Kolean - CFO Jarrod Longcor - COO Anne Marie...

2 months ago · seekingalpha.com
Cellectar Biosciences Inc. (CLRB) Q4 2024 Earnings Call TranscriptCellectar Biosciences Inc. (NASDAQ:CLRB ) Q4 2024 Earnings Conference Call March 13, 2025 8:30 AM ET Company Participants Anne Marie Fields – Managing Director-Precision AQ Jim Caruso – President and ...